Finance

Lists
Q3 2026 earnings • released • EPS miss -0.60%
See results
SVRA:NASDAQ
Savara Inc
$5.10
+3.66%
(+0.18) 1D
Nov 11, 12:12:40 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SVRA...
Open
$4.99
High
$5.20
Low
$4.91
Mkt. cap
1.05B
Avg. vol.
2.56M
Volume
1.15M
52-wk high
$7.00
52-wk low
$4.05
EPS
-$0.58
Beta
0.32
Shares outstanding
220.62M
No. of employees
70
Open
$4.99
High
$5.20
Low
$4.91
Mkt. cap
1.05B
Avg. vol.
2.56M
Volume
1.15M
52-wk high
$7.00
52-wk low
$4.05
EPS
-$0.58
Beta
0.32
Shares outstanding
220.62M
No. of employees
70
News stories
From web sources and news partners
About Savara Inc
CEO-
Employees70
Founded1995
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitesavarapharma.com
Analyst ratings
Based on 6 analysts giving stock ratings to SVRA in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for SVRA in the last 3 months.
Highest
Current $5.10
$16.00 (+213.73%)
Average
$11.67 (+128.82%)
Lowest
$10.00 (+96.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Maintained
$11.00
+115.7%
11/11/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$10.00
+96.1%
10/27/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$16.00
+213.7%
10/26/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$12.00
+135.3%
10/07/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$11.00
+115.7%
08/20/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$10.00
+96.1%
08/12/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$9.00
+76.5%
08/11/2026
Andreas Argyrides
Chardan Capital
Buy
Maintained
$11.00
+115.7%
06/03/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$0.17 / -$0.17
-0.60%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
20.59M
20.90M
-
21.95M
Cost of revenue
20.59M
20.90M
-
21.95M
Research and development expenses
-
-
23.40M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.63M
12.53M
15.57M
18.99M
Operating expense
9.66M
12.52M
38.14M
19.01M
Total operating expenses
30.26M
33.42M
38.14M
40.96M
Operating income
-30.26M
-33.42M
-38.14M
-40.96M
Other non operating income
-
-
12.00K
-11.00K
EBT including unusual items
-29.56M
-32.24M
-37.28M
-40.23M
EBT excluding unusual items
-29.56M
-32.24M
-37.28M
-40.23M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-853.00K
-
Net income
-29.56M
-32.24M
-37.28M
-40.23M
Net profit margin
-
-
-
-
Earnings per share
-0.14
-0.13
-0.15
-0.16
Interest and investment income
548.00K
1.20M
1.06M
829.00K
Interest expense
-
-
-
-
Net interest expenses
548.00K
1.20M
1.06M
829.00K
Depreciation and amortization charges
36.00K
-11.00K
24.00K
28.00K
EBITDA
-30.22M
-33.40M
-38.11M
-40.94M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps